Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
Abstract Aim Multiple studies have revealed the correlation between gut microbiome and the response to checkpoint inhibitors (CPIs) in patients with cancer, and oral administration of butyrate‐producing enterobacteria has been reported to enhance the efficacy of CPIs. However, the effects of enterob...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-09-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6416 |
| _version_ | 1797672354692726784 |
|---|---|
| author | Kazuhiro Nouso Shohei Shiota Rio Fujita Akiko Wakuta Kazuya Kariyama Atsushi Hiraoka Masanori Atsukawa Joji Tani Toshifumi Tada Shinichiro Nakamura Kazuto Tajiri Masaki Kaibori Masashi Hirooka Ei Itobayashi Satoru Kakizaki Atsushi Naganuma Toru Ishikawa Takeshi Hatanaka Shinya Fukunishi Kunihiko Tsuji Kazuhito Kawata Koichi Takaguchi Akemi Tsutsui Chikara Ogawa Hironori Ochi Yutaka Yata Hidekatsu Kuroda Hiroko Iijima Tomomitsu Matono Noritomo Shimada Satoshi Yasuda Hidenori Toyoda Takashi Kumada the Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) |
| author_facet | Kazuhiro Nouso Shohei Shiota Rio Fujita Akiko Wakuta Kazuya Kariyama Atsushi Hiraoka Masanori Atsukawa Joji Tani Toshifumi Tada Shinichiro Nakamura Kazuto Tajiri Masaki Kaibori Masashi Hirooka Ei Itobayashi Satoru Kakizaki Atsushi Naganuma Toru Ishikawa Takeshi Hatanaka Shinya Fukunishi Kunihiko Tsuji Kazuhito Kawata Koichi Takaguchi Akemi Tsutsui Chikara Ogawa Hironori Ochi Yutaka Yata Hidekatsu Kuroda Hiroko Iijima Tomomitsu Matono Noritomo Shimada Satoshi Yasuda Hidenori Toyoda Takashi Kumada the Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) |
| author_sort | Kazuhiro Nouso |
| collection | DOAJ |
| description | Abstract Aim Multiple studies have revealed the correlation between gut microbiome and the response to checkpoint inhibitors (CPIs) in patients with cancer, and oral administration of butyrate‐producing enterobacteria has been reported to enhance the efficacy of CPIs. However, the effects of enterobacteria on patients with hepatocellular carcinoma (HCC) are not well understood. Methods In this retrospective multicenter study, we enrolled 747 patients with advanced HCC, treated with atezolizumab and bevacizumab combination therapy. Tumor response, survival, and adverse effects were compared between 99 patients who ingested drugs containing butyric acid‐producing enterobacteria (butyric acid group) and the remaining patients (control group). Results Objective response and disease control rates in butyric acid group (29.7% and 77.8%, respectively) were higher than those in the control group (26.4% and 72.7%, respectively). However, the differences were not statistically significant (p = 0.543 and p = 0.222, respectively). No difference in median survival time was observed between the two groups (20.0 months and 21.4 months, respectively; p = 0.789), even after matching the backgrounds of the patients with propensity scores (p = 0.714). No adverse effects occurred upon the administration of butyrate‐producing bacteria. However, proteinuria (41.4% vs. 30.9%; p = 0.041), fever (17.2% vs. 10.2%, p = 0.036), and diarrhea (15.2% vs. 6.2%; p = 0.001) occurred more frequently in the butyric acid group. Conclusion Butyrate‐producing bacteria does not enhance the efficacy of atezolizumab–bevacizumab combination therapy in patients with HCC. |
| first_indexed | 2024-03-11T21:28:44Z |
| format | Article |
| id | doaj.art-63364b06136f40709acc82310c3985ee |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-11T21:28:44Z |
| publishDate | 2023-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-63364b06136f40709acc82310c3985ee2023-09-27T11:46:08ZengWileyCancer Medicine2045-76342023-09-011217178491785510.1002/cam4.6416Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumabKazuhiro Nouso0Shohei Shiota1Rio Fujita2Akiko Wakuta3Kazuya Kariyama4Atsushi Hiraoka5Masanori Atsukawa6Joji Tani7Toshifumi Tada8Shinichiro Nakamura9Kazuto Tajiri10Masaki Kaibori11Masashi Hirooka12Ei Itobayashi13Satoru Kakizaki14Atsushi Naganuma15Toru Ishikawa16Takeshi Hatanaka17Shinya Fukunishi18Kunihiko Tsuji19Kazuhito Kawata20Koichi Takaguchi21Akemi Tsutsui22Chikara Ogawa23Hironori Ochi24Yutaka Yata25Hidekatsu Kuroda26Hiroko Iijima27Tomomitsu Matono28Noritomo Shimada29Satoshi Yasuda30Hidenori Toyoda31Takashi Kumada32the Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)Department of Gastroenterology Okayama City Hospital Okayama JapanDepartment of Gastroenterology Okayama City Hospital Okayama JapanDepartment of Gastroenterology Okayama City Hospital Okayama JapanDepartment of Gastroenterology Okayama City Hospital Okayama JapanDepartment of Gastroenterology Okayama City Hospital Okayama JapanGastroenterology Center Ehime Prefectural Central Hospital Matsuyama JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo JapanDepartment of Gastroenterology and Hepatology Kagawa University Takamatsu JapanDepartment of Internal Medicine Japanese Red Cross Society Himeji Hospital Himeji JapanDepartment of Internal Medicine Japanese Red Cross Society Himeji Hospital Himeji JapanDepartment of Gastroenterology Toyama University Hospital Toyama JapanDepartment of Surgery Kansai Medical University Hirakata JapanDepartment of Gastroenterology and Metabology Ehime University Graduate School of Medicine Toon JapanDepartment of Gastroenterology Asahi General Hospital Asahi JapanDepartment of Clinical Research National Hospital Organization Takasaki General Medical Center Takasaki JapanDepartment of Gastroenterology National Hospital Organization Takasaki General Medical Center Takasaki JapanDepartment of Gastroenterology Saiseikai Niigata Hospital Niigata JapanDepartment of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi JapanDepartment of Gastroenterology Osaka Medical and Pharmaceutical University Osaka JapanGastroenterology Center, Teine Keijinkai Hospital Sapporo JapanHepatology Division, Department of Internal Medicine II Hamamatsu University School of Medicine Hamamatsu JapanDepartment of Hepatology Kagawa Prefectural Central Hospital Takamatsu JapanDepartment of Hepatology Kagawa Prefectural Central Hospital Takamatsu JapanDepartment of Gastroenterology Japanese Red Cross Takamatsu Hospital Takamatsu JapanCenter for Liver‐Biliary‐Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama JapanDepartment of Gastroenterology Hanwa Memorial Hospital Osaka JapanDepartment of Gastroenterology Iwate Medical University Iwate JapanDivision of Gastroenterology and Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine Hyogo Medical University Himeji JapanDepartment of Gastroenterology and Hepatology St. Mary's Hospital Himeji JapanDivision of Gastroenterology and Hepatology Otakanomori Hospital Kashiwa JapanDepartment of Gastroenterology and Hepatology Ogaki Municipal Hospital Gifu JapanDepartment of Gastroenterology and Hepatology Ogaki Municipal Hospital Gifu JapanDepartment of Nursing Gifu Kyoritsu University Ogaki JapanAbstract Aim Multiple studies have revealed the correlation between gut microbiome and the response to checkpoint inhibitors (CPIs) in patients with cancer, and oral administration of butyrate‐producing enterobacteria has been reported to enhance the efficacy of CPIs. However, the effects of enterobacteria on patients with hepatocellular carcinoma (HCC) are not well understood. Methods In this retrospective multicenter study, we enrolled 747 patients with advanced HCC, treated with atezolizumab and bevacizumab combination therapy. Tumor response, survival, and adverse effects were compared between 99 patients who ingested drugs containing butyric acid‐producing enterobacteria (butyric acid group) and the remaining patients (control group). Results Objective response and disease control rates in butyric acid group (29.7% and 77.8%, respectively) were higher than those in the control group (26.4% and 72.7%, respectively). However, the differences were not statistically significant (p = 0.543 and p = 0.222, respectively). No difference in median survival time was observed between the two groups (20.0 months and 21.4 months, respectively; p = 0.789), even after matching the backgrounds of the patients with propensity scores (p = 0.714). No adverse effects occurred upon the administration of butyrate‐producing bacteria. However, proteinuria (41.4% vs. 30.9%; p = 0.041), fever (17.2% vs. 10.2%, p = 0.036), and diarrhea (15.2% vs. 6.2%; p = 0.001) occurred more frequently in the butyric acid group. Conclusion Butyrate‐producing bacteria does not enhance the efficacy of atezolizumab–bevacizumab combination therapy in patients with HCC.https://doi.org/10.1002/cam4.6416atezolizumabbevacizumabbutyrate‐producing enterobacteriahepatocellular carcinoma |
| spellingShingle | Kazuhiro Nouso Shohei Shiota Rio Fujita Akiko Wakuta Kazuya Kariyama Atsushi Hiraoka Masanori Atsukawa Joji Tani Toshifumi Tada Shinichiro Nakamura Kazuto Tajiri Masaki Kaibori Masashi Hirooka Ei Itobayashi Satoru Kakizaki Atsushi Naganuma Toru Ishikawa Takeshi Hatanaka Shinya Fukunishi Kunihiko Tsuji Kazuhito Kawata Koichi Takaguchi Akemi Tsutsui Chikara Ogawa Hironori Ochi Yutaka Yata Hidekatsu Kuroda Hiroko Iijima Tomomitsu Matono Noritomo Shimada Satoshi Yasuda Hidenori Toyoda Takashi Kumada the Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab Cancer Medicine atezolizumab bevacizumab butyrate‐producing enterobacteria hepatocellular carcinoma |
| title | Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab |
| title_full | Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab |
| title_fullStr | Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab |
| title_full_unstemmed | Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab |
| title_short | Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab |
| title_sort | effect of butyrate producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab |
| topic | atezolizumab bevacizumab butyrate‐producing enterobacteria hepatocellular carcinoma |
| url | https://doi.org/10.1002/cam4.6416 |
| work_keys_str_mv | AT kazuhironouso effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT shoheishiota effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT riofujita effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT akikowakuta effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT kazuyakariyama effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT atsushihiraoka effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT masanoriatsukawa effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT jojitani effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT toshifumitada effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT shinichironakamura effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT kazutotajiri effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT masakikaibori effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT masashihirooka effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT eiitobayashi effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT satorukakizaki effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT atsushinaganuma effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT toruishikawa effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT takeshihatanaka effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT shinyafukunishi effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT kunihikotsuji effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT kazuhitokawata effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT koichitakaguchi effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT akemitsutsui effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT chikaraogawa effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT hironoriochi effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT yutakayata effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT hidekatsukuroda effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT hirokoiijima effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT tomomitsumatono effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT noritomoshimada effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT satoshiyasuda effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT hidenoritoyoda effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT takashikumada effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab AT thereallifepracticeexpertsforhccrelpecstudygroupandhcc48grouphepatocellularcarcinomaexpertsfrom48clinicsinjapan effectofbutyrateproducingenterobacteriaonadvancedhepatocellularcarcinomatreatmentwithatezolizumabandbevacizumab |